hotspot -WSS

hotspot

author：fashion 2025-09-27 10:04:31 - browse：39

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA approves first blood sugar monitor without finger pricks

WSS

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Medicare Advantage beneficiaries sue Humana over algorithm use

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

FAMU bans football players from facility after release of rap video shot in team's locker room

Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

Why health care costs have stayed mostly flat since 2010

After affirmative action ruling, medical educators look to 'holistic review'

Thousands protest mob assault of women who were paraded naked in remote Indian border state

DIEP, the 'gold standard' of breast reconstruction, is under threat

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Medicare proposal to cover medical devices draws a mixed reaction

New requirements coming in 2024 for Americans traveling to Europe

Hollywood unions extend contract negotiations for actors

SEC charges former device maker CEO with $41 million fraud

knowledge

Inside the culture of fear in the White House science office of Eric Lander

Medicare drug price negotiation hasn't dried up venture capital

Drinking less cuts risk of oral cavity, esophageal cancer: Report

FAMU bans football players from facility after release of rap video shot in team's locker room

The response to Covid

Prime Medicine, Myeloid Therapeutics clash over genome

focus

knowledge

focus

Wikipedia